Targeted Therapy

Breast cancers are also tested for special receptors. One such receptor is the Human Epidermal Growth Factor 2 (HER2) receptor. This receptor is overexpressed in about 25 percent of all breast cancers; the presence needs to be confirmed by laboratory tests performed on the biopsy specimen before the treatment is given.

The aim of the treatment is to reduce and hopefully eliminate existing cancer cells in the human body while minimising side effects on normal cells.

Trastuzumab, also known as Herceptin®, targets the HER2 (Human Epidermal Growth Factor 2) receptors on cancer cells to prevent cell growth and division.

Herceptin® has been shown to prolong survival in breast cancer patients with early and advanced disease (Stage IV) when used in combination with chemotherapy.

Side Effects:

• Patients who receive trastuzumab may complain of infusion-related reactions such as fever and chills. Rarely, weakening of the heart muscles (also known as cardiomyopathy) has been observed in some patients.

An increasing number of targeted drugs are becoming available for the treatment of breast cancer, including Lapatinib (which targets HER2 and EGFR) and Bevacizumab (which targets a factor associated with new blood vessel formation in tumours).

Condition treated at:

 National Cancer Centre Singapore

 Singapore General Hospital

 Changi General Hospital

 Sengkang General Hospital

 KK Women's and Children's Hospital